Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Jan;51(1):99-102.
doi: 10.1046/j.1365-2125.2001.01324.x.

Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro

K Jones  1 , P G Hoggard, S Khoo, B Maher, D J Back
Affiliations
Comparative Study

Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro

K Jones et al. Br J Clin Pharmacol. 2001 Jan.

Abstract

Aims: Since alpha1-acid glycoprotein (AGP) levels may be raised during HIV infection, we have examined in vitro the effect of increasing the concentration of AGP on the intracellular accumulation of the HIV protease inhibitors saquinavir (SQV), ritonavir (RTV) and indinavir (IDV).

Methods: U937 cells (5 x 10(6) cells in 5 ml RPMI growth medium) were incubated at 37 degrees C for 18 h with [14C]-SQV (0.1 microCi), [3H]-RTV and [3H]-IDV (0.135 microCi) to a final concentration of 1 microM in the presence of 0, 0.5 and 2.0 mg x ml(-1) AGP. Following extraction in 60% methanol the intracellular drug concentration was determined by liquid scintillation counting.

Results: Binding to AGP (2.0 mg x ml(-1)) reduced the mean intracellular concentration of SQV from 31.5 microM to 7.4 microM (P < 0.0001; 95% CI 19.4-28.8). RTV concentration was also reduced (8.8 microM to 1.6 microM; P < 0.0001; 95% CI 5.4-9.0) as was the concentration of IDV (3.0 microM to 1.5 microM; P < 0.0001; 95% CI 1.1-1.9).

Conclusions: Reduced intracellular protease inhibitor concentrations in the presence of increasing concentrations of AGP will certainly impact on the antiviral activity in vitro. However, since protease inhibitors are high clearance drugs, free drug concentration will likely remain unaffected in the presence of elevated AGP during chronic oral dosing although there will be an increase in total plasma drug concentration.

PubMed Disclaimer

References

    1. Barry M, Gibbons S, Mulcahy F, Back D. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokin. 1997;32:99–102. - PubMed
    1. Denissen JF, Grabowski BA, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997;25:489–501. - PubMed
    1. Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997;19:159–175. - PubMed
    1. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human α1 acid glycoprotein in health and disease. Pharmac Rev. 1988;40:1–47. - PubMed
    1. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia: Williams & Wilkins; 1995. pp. 137–155.

Publication types